A new expert review, authored by over 25 scientists including clinicians and leading experts in aging biology and metabolism, highlights the growing global interest in nicotinamide adenine dinucleotide (NAD+). This comprehensive paper brings together diverse insights to explore how this vital molecule might support healthier aging and offer protection against conditions such as Alzheimer’s and Parkinson’s disease.
Often referred to as a cell’s ‘fuel regulator,’ NAD+ is fundamental to cellular energy production, DNA repair, and overall cell function. However, its levels naturally decline with age, a phenomenon linked to cognitive issues, reduced physical strength, and an increased risk of age-related illnesses.
One of the lead authors stated that optimizing NAD+ metabolism shows promise for delaying age-related health decline and mitigating diseases associated with premature aging. However, they stressed the importance of understanding appropriate dosages, long-term safety, and individual responses to NAD+ boosting strategies to fully harness its potential.
Research spanning years of laboratory work and early clinical studies investigating methods to elevate NAD+ levels were examined in the review. Many of these approaches involve vitamin-like compounds known as NAD+ precursors, such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Initial findings are encouraging, with some trials reporting improvements in memory, physical mobility, and metabolic well-being. Nevertheless, researchers emphasize the necessity of larger and more extended patient studies to confirm the efficacy of these interventions across different diseases.
This publication emerges amidst increasing scientific and public fascination with NAD+ therapies. Clinical trials are currently underway globally to test NAD+ precursors, while these compounds have also entered a rapidly expanding supplement market. This has sparked discussions regarding the most effective options and whether findings from animal studies will translate effectively to human health.
A senior author and head of one of the contributing laboratories commented on the timely nature of this expert opinion, noting that while NAD+ is essential for life, there remains considerable confusion and debate regarding the best supplements and their proper use. The article aims to consolidate existing evidence and provide a scientific roadmap for ongoing research and future clinical applications.
Another co-author highlighted a knowledge gap among basic researchers and clinicians regarding NAD+ and its clinical effects. This review serves to offer the latest expert perspective to those engaged in NAD+ research and will provide valuable information for numerous NAD+-based clinical trials across a wide spectrum of conditions, including neurological and cardiovascular diseases.
The authors conclude by underscoring that despite the widespread investigation into NAD+-based supplements and therapies, enhanced collaboration and more rigorous clinical testing are crucial. These steps are vital for transforming initial findings into safe and effective treatments for aging and age-related diseases.